Archive - December 2021
COVID-19 Omicron Symptoms Based On Vaccine, Vaccination Status
2021 headlines: Pharma’s top five stumbles, spectacles and controversies
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
Hyloris Announces FDA Acceptance of New Drug Application for Maxigesic IV in Post-Operative Pain
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
Amylyx Pharmaceuticals Submits New Drug Application (NDA) for AMX0035 for the Treatment of ALS
FDA Grants Tentative Approval for Liquidia’s Yutrepia (treprostinil) Inhalation Powder